Promising drug targets tough mesothelioma in early trial

NCT ID NCT06477419

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called sacituzumab govitecan in 33 adults with mesothelioma that has come back or spread. Participants receive the drug until their disease worsens or side effects become too severe. The main goal is to see if the drug can shrink tumors and help control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE PLEURAL MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffused pleural mesothelioma malignant pleural mesothelioma mesothelioma Mesothelioma, Malignant pleural mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESOTHELIOMA MESOTHELIOMA; PLEURA MESOTHELIOMAS PLEURAL

Contacts and locations

Locations

Memorial Sloan - Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
Memorial Sloan Kettering Basking Ridge
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center @ Commack
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.